Literature DB >> 22797646

Current approaches to tuberculosis in the United States.

Fred M Gordin1, Henry Masur.   

Abstract

Tuberculosis is a major threat to global health, infecting a third of the world's population. In the United States, however, control of tuberculosis has been increasingly successful. Only 3.2% of the US population is estimated to have latent tuberculosis and there are only 11,000 cases annually of active disease. More than half the cases in this country occur in individuals born outside the United States. Human immunodeficiency virus coinfection is not a major factor in the United States, since only approximately 10% of cases are coinfected. Drug resistance is also uncommon in this country. Because the United States has more resources for the diagnosis, therapy, and public health control of tuberculosis than many regions of the world, and because many hospitals have more cases of clinically significant nontuberculous mycobacteria than tuberculosis, the management approaches to tuberculosis need to be quite different in this country than in other regions. The resurgence in interest in developing new tools and the investment in public health infrastructure will hopefully be sustained in the United States so that the effect of tuberculosis on the US population will continue to diminish, and these new tools and approaches can be adapted to both high and low prevalence areas to meet the global challenge.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22797646      PMCID: PMC4183067          DOI: 10.1001/jama.2012.7505

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  46 in total

Review 1.  Global tuberculosis drug development pipeline: the need and the reality.

Authors:  Zhenkun Ma; Christian Lienhardt; Helen McIlleron; Andrew J Nunn; Xiexiu Wang
Journal:  Lancet       Date:  2010-05-18       Impact factor: 79.321

2.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

Authors:  Andreas H Diacon; Alexander Pym; Martin Grobusch; Ramonde Patientia; Roxana Rustomjee; Liesl Page-Shipp; Christoffel Pistorius; Rene Krause; Mampedi Bogoshi; Gavin Churchyard; Amour Venter; Jenny Allen; Juan Carlos Palomino; Tine De Marez; Rolf P G van Heeswijk; Nacer Lounis; Paul Meyvisch; Johan Verbeeck; Wim Parys; Karel de Beule; Koen Andries; David F Mc Neeley
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

3.  Changes in the transmission of tuberculosis in New York City from 1990 to 1999.

Authors:  Elvin Geng; Barry Kreiswirth; Cynthia Driver; Jiehui Li; Joseph Burzynski; Phyllis DellaLatta; Angel LaPaz; Neil W Schluger
Journal:  N Engl J Med       Date:  2002-05-09       Impact factor: 91.245

Review 4.  A systematic review of rapid diagnostic tests for the detection of tuberculosis infection.

Authors:  J Dinnes; J Deeks; H Kunst; A Gibson; E Cummins; N Waugh; F Drobniewski; A Lalvani
Journal:  Health Technol Assess       Date:  2007-01       Impact factor: 4.014

5.  Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.

Authors:  William J Burman; Stefan Goldberg; John L Johnson; Grace Muzanye; Melissa Engle; Ann W Mosher; Shurjeel Choudhri; Charles L Daley; Sonal S Munsiff; Zhen Zhao; Andrew Vernon; Richard E Chaisson
Journal:  Am J Respir Crit Care Med       Date:  2006-05-04       Impact factor: 21.405

6.  Tuberculosis then and now: a personal perspective on the last 50 years.

Authors:  G L Snider
Journal:  Ann Intern Med       Date:  1997-02-01       Impact factor: 25.391

Review 7.  Viewpoint TB diagnostics: what does the world really need?

Authors:  Karin Weyer; Susanne Carai; Paul Nunn
Journal:  J Infect Dis       Date:  2011-11-15       Impact factor: 5.226

8.  Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients.

Authors:  C Beck-Sagué; S W Dooley; M D Hutton; J Otten; A Breeden; J T Crawford; A E Pitchenik; C Woodley; G Cauthen; W R Jarvis
Journal:  JAMA       Date:  1992-09-09       Impact factor: 56.272

Review 9.  Tuberculosis outbreak investigations in the United States, 2002-2008.

Authors:  Kiren Mitruka; John E Oeltmann; Kashef Ijaz; Maryam B Haddad
Journal:  Emerg Infect Dis       Date:  2011-03       Impact factor: 6.883

10.  Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.

Authors:  Ian M Rosenthal; Ming Zhang; Kathy N Williams; Charles A Peloquin; Sandeep Tyagi; Andrew A Vernon; William R Bishai; Richard E Chaisson; Jacques H Grosset; Eric L Nuermberger
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

View more
  6 in total

1.  Doubled Nontuberculous Mycobacteria Isolation as a Consequence of Changes in the Diagnosis Algorithm.

Authors:  Suting Chen; Fen Wang; Yi Xue; Fengmin Huo; Junnan Jia; Lingling Dong; Liping Zhao; Guanglu Jiang; Hairong Huang
Journal:  Infect Drug Resist       Date:  2022-06-27       Impact factor: 4.177

2.  Design, Synthesis and Biological Evaluation of Some Triazole Schiff's Base Derivatives as Potential Antitubercular Agents.

Authors:  Asma A Sager; Zainab S Abood; Wedad M El-Amary; Salah M Bensaber; Inass A Al-Sadawe; Nouri B Ermeli; Salah B Mohamed; Mohamed Al-Forgany; Ibrahim A Mrema; Mabrouk Erhuma; Anton Hermann; Abdul M Gbaj
Journal:  Open Med Chem J       Date:  2018-04-30

3.  Application of Pulsed Field Gel Electrophoresis for Study of Genetic Diversity in Mycobacterium tuberculosis Strains Isolated From Tuberculosis Patients.

Authors:  Azar Dokht Khosravi; Shideh Vatani; Mohammad Mehdi Feizabadi; Effat Abasi Montazeri; Abbas Jolodar
Journal:  Jundishapur J Microbiol       Date:  2014-05-01       Impact factor: 0.747

4.  A cost-benefit analysis of a proposed overseas refugee latent tuberculosis infection screening and treatment program.

Authors:  La'Marcus T Wingate; Margaret S Coleman; Christopher de la Motte Hurst; Marie Semple; Weigong Zhou; Martin S Cetron; John A Painter
Journal:  BMC Public Health       Date:  2015-12-01       Impact factor: 3.295

5.  Timing of treatment interruption among latently infected tuberculosis cases treated with a nine-month course of daily isoniazid: findings from a time to event analysis.

Authors:  Marie Nancy Séraphin; HsiaoChu Hsu; Helena J Chapman; Joanne L de Andrade Bezerra; Lori Johnston; Yang Yang; Michael Lauzardo
Journal:  BMC Public Health       Date:  2019-09-03       Impact factor: 3.295

6.  Peritoneal tuberculosis in an immunocompetent, unknown risk patient.

Authors:  Yutaka Tomizawa; Emmanuelle B Yecies; Fiona E Craig; Adam Sohnen
Journal:  Case Rep Gastrointest Med       Date:  2013-06-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.